Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors
出版年份 2018 全文链接
标题
Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 19, Issue 8, Pages 2367
出版商
MDPI AG
发表日期
2018-08-13
DOI
10.3390/ijms19082367
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cytochromes P450 1A2 and 3A4 Catalyze the Metabolic Activation of Sunitinib
- (2018) Gracia M. Amaya et al. CHEMICAL RESEARCH IN TOXICOLOGY
- LC-MS/MS reveals the formation of reactive ortho -quinone and iminium intermediates in saracatinib metabolism: Phase I metabolic profiling
- (2018) Mohamed W. Attwa et al. CLINICA CHIMICA ACTA
- Identification of Ketene-Reactive Intermediate of Erlotinib Possibly Responsible for Inactivation of P450 Enzymes
- (2018) Huimin Zhao et al. DRUG METABOLISM AND DISPOSITION
- Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines
- (2017) Cécile Mingard et al. JOURNAL OF APPLIED TOXICOLOGY
- Novel Pathways of Ponatinib Disposition Catalyzed By CYP1A1 Involving Generation of Potentially Toxic Metabolites
- (2017) De Lin et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Identification and characterization of in vitro phase I and reactive metabolites of masitinib using a LC-MS/MS method: bioactivation pathway elucidation
- (2017) Sawsan M. Amer et al. RSC Advances
- Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis
- (2017) Franziska Paech et al. Frontiers in Pharmacology
- Effects of 31 FDA approved small-molecule kinase inhibitors on isolated rat liver mitochondria
- (2016) Jun Zhang et al. ARCHIVES OF TOXICOLOGY
- P450 3A-Catalyzed O-Dealkylation of Lapatinib Induces Mitochondrial Stress and Activates Nrf2
- (2016) Marsha Rebecca Eno et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Cytochrome P450 Mediated Bioactivation of Saracatinib
- (2016) Jiaming Chen et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Small-molecule kinase inhibitors: an analysis of FDA-approved drugs
- (2016) Peng Wu et al. DRUG DISCOVERY TODAY
- Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
- (2016) Jeffrey H Lipton et al. LANCET ONCOLOGY
- Predicting Toxicities of Reactive Metabolite–Positive Drug Candidates
- (2015) Amit S. Kalgutkar et al. Annual Review of Pharmacology and Toxicology
- Metabolism-related pharmacokinetic drug−drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations
- (2015) Yi Ling Teo et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer
- (2015) C.-F. Xu et al. CLINICAL CANCER RESEARCH
- Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials
- (2015) Pooja Ghatalia et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib
- (2015) Han Kiat Ho et al. DRUG METABOLISM REVIEWS
- Sunitinib-ibuprofen drug interaction affects the pharmacokinetics and tissue distribution of sunitinib to brain, liver, and kidney in male and female mice differently
- (2015) Christine Li Ling Lau et al. FUNDAMENTAL & CLINICAL PHARMACOLOGY
- The chemical, genetic and immunological basis of idiosyncratic drug–induced liver injury
- (2015) A Tailor et al. HUMAN & EXPERIMENTAL TOXICOLOGY
- Metabolic activation and drug-induced liver injury:in vitroapproaches for the safety risk assessment of new drugs
- (2015) M. José Gómez-Lechón et al. JOURNAL OF APPLIED TOXICOLOGY
- Drug-induced liver injury: Interactions between drug properties and host factors
- (2015) Minjun Chen et al. JOURNAL OF HEPATOLOGY
- Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations
- (2015) Eri Sugiyama et al. LUNG CANCER
- Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients
- (2015) Y L Teo et al. PHARMACOGENOMICS JOURNAL
- Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01
- (2015) L R Parham et al. PHARMACOGENOMICS JOURNAL
- Regorafenib impairs mitochondrial functions, activates AMP-activated protein kinase, induces autophagy, and causes rat hepatocyte necrosis
- (2015) Zuquan Weng et al. TOXICOLOGY
- Review Hepatotoxicity of molecular targeted therapy
- (2015) Bożenna Karczmarek-Borowska et al. Wspolczesna Onkologia-Contemporary Oncology
- Regorafenib
- (2014) Daniel J. Crona et al. ANNALS OF PHARMACOTHERAPY
- Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms
- (2014) Sariah Liu et al. CANCER TREATMENT REVIEWS
- Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review
- (2014) Yi Ling Teo et al. Expert Opinion on Drug Metabolism & Toxicology
- Prospective Validation ofHLA-DRB1*07:01Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury
- (2014) Daniel J. Schaid et al. JOURNAL OF CLINICAL ONCOLOGY
- Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives
- (2013) Rashmi R. Shah et al. DRUG SAFETY
- Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors
- (2013) Colin F Spraggs et al. PHARMACOGENOMICS
- Structural identification of imatinib cyanide adducts by mass spectrometry and elucidation of bioactivation pathway
- (2013) Austin C. Li et al. RAPID COMMUNICATIONS IN MASS SPECTROMETRY
- Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence
- (2012) Yi Ling Teo et al. BREAST CANCER RESEARCH AND TREATMENT
- Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients
- (2012) Cen Xie et al. BRITISH JOURNAL OF PHARMACOLOGY
- Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: A meta-analysis
- (2012) Yi Ling Teo et al. CANCER TREATMENT REVIEWS
- Lapatinib-Induced Liver Injury Characterized by Class II HLA and Gilbert's Syndrome Genotypes
- (2012) C F Spraggs et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The HepaRG cell line: a uniquein vitrotool for understanding drug metabolism and toxicology in human
- (2012) Tommy B Andersson et al. Expert Opinion on Drug Metabolism & Toxicology
- The Generation, Detection, and Effects of Reactive Drug Metabolites
- (2012) Andrew V. Stachulski et al. MEDICINAL RESEARCH REVIEWS
- Drug–Drug Interaction Potential of Marketed Oncology Drugs: In Vitro Assessment of Time-Dependent Cytochrome P450 Inhibition, Reactive Metabolite Formation and Drug–Drug Interaction Prediction
- (2012) Jane R. Kenny et al. PHARMACEUTICAL RESEARCH
- Oxidative stress is involved in Dasatinib-induced apoptosis in rat primary hepatocytes
- (2012) Tao Xue et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Bioactivation of Drugs: Risk and Drug Design
- (2011) John S. Walsh et al. Annual Review of Pharmacology and Toxicology
- Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States
- (2011) Antonia F. Stepan et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Metabolic Intermediate Complex Formation of Human Cytochrome P450 3A4 by Lapatinib
- (2011) H. Takakusa et al. DRUG METABOLISM AND DISPOSITION
- HLA-DQA1*02:01 Is a Major Risk Factor for Lapatinib-Induced Hepatotoxicity in Women With Advanced Breast Cancer
- (2011) Colin F. Spraggs et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytochrome P450-Mediated Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Erlotinib to a Reactive Electrophile
- (2010) X. Li et al. DRUG METABOLISM AND DISPOSITION
- Metabolism considerations for kinase inhibitors in cancer treatment
- (2010) Derek R Duckett et al. Expert Opinion on Drug Metabolism & Toxicology
- HepaRG cells: A human model to study mechanisms of acetaminophen hepatotoxicity
- (2010) Mitchell R. McGill et al. HEPATOLOGY
- Mechanism-Based Inactivation of Cytochrome P450 3A4 by Lapatinib
- (2010) W. C. Teng et al. MOLECULAR PHARMACOLOGY
- Clinical pharmacokinetics of tyrosine kinase inhibitors
- (2009) Nielka P. van Erp et al. CANCER TREATMENT REVIEWS
- Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Gefitinib: Implications for Pulmonary and Hepatic Toxicities
- (2009) Xiaohai Li et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Can In Vitro Metabolism-Dependent Covalent Binding Data Distinguish Hepatotoxic from Nonhepatotoxic Drugs? An Analysis Using Human Hepatocytes and Liver S-9 Fraction
- (2009) Jonathon N. Bauman et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Current Concepts of Mechanisms in Drug-Induced Hepatotoxicity
- (2009) Stefan Russmann et al. CURRENT MEDICINAL CHEMISTRY
- Stable Expression, Activity, and Inducibility of Cytochromes P450 in Differentiated HepaRG Cells
- (2009) S. Antherieu et al. DRUG METABOLISM AND DISPOSITION
- Characterization of Dasatinib and Its Structural Analogs as CYP3A4 Mechanism-Based Inactivators and the Proposed Bioactivation Pathways
- (2009) X. Li et al. DRUG METABOLISM AND DISPOSITION
- Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530
- (2009) Tim P. Green et al. Molecular Oncology
- Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
- (2009) Patrice Dubreuil et al. PLoS One
- Role of Hepatic Transporters in the Disposition and Hepatotoxicity of a HER2 Tyrosine Kinase Inhibitor CP-724,714
- (2009) Bo Feng et al. TOXICOLOGICAL SCIENCES
- Can In Vitro Metabolism-Dependent Covalent Binding Data in Liver Microsomes Distinguish Hepatotoxic from Nonhepatotoxic Drugs? An Analysis of 18 Drugs with Consideration of Intrinsic Clearance and Daily Dose
- (2008) R. Scott Obach et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
- Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
- (2008) P MEDINA et al. CLINICAL THERAPEUTICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started